Leukemic cells from 30% of patients with acute myeloid leukemia (AML) have an activating
mutation in the FLT3 (fms-like tyrosine kinase) gene, which represents a target for drug …

FLT3 is a receptor tyrosine kinase with important roles in hematopoietic stem/progenitor cell
survival and proliferation. It is mutated in about 1/3 of acute myeloid leukemia (AML) …

Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approximately 30%
of patients with de novo acute myeloid leukemia (AML) and are associated with lower cure …

Activating mutations in the FLT3 tyrosine kinase (TK) occur in approximately 35% of patients
with acute myeloid leukemia (AML). Therefore, targeting mutated FLT3 is an attractive …

Fms-like tyrosine kinase 3 (FLT3) receptor mutations as internal tandem duplication (ITD) or
within the kinase domain are detected in up to 35% of patients with acute myeloid leukemia …

Internal tandem duplication mutations of FLT3 (FLT3/ITD mutations) are common in acute
myeloid leukemia (AML) and confer a poor prognosis. This would suggest that FLT3 is an …

Internal tandem duplication (ITD) mutations of the receptor tyrosine kinase FLT3 have been
found in 20% to 30% of patients with acute myeloid leukemia (AML). These mutations …

Mutations in the receptor tyrosine kinase FLT3 occur frequently in patients with acute
myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Small molecules that …

The receptor tyrosine kinase FLT3 is a promising molecular therapeutic target in acute
myeloid leukemia (AML). Activating mutations of FLT3 are present in approximately one …

Constitutively activating FLT3 receptor mutations have been found in 35% of patients with
acute myeloblastic leukemia (AML). Here we report the identification of a small molecule …